The Canadian government has authorized a startup to export psychedelic substances to Australia for medicinal purposes. Optimi Health Corp. is charged with distributing pills laced with psilocybin, an extract from magic mushrooms, and MDMA, as sanctioned by the health department.
The growing demand for these substances is not confined to the local magic mushrooms Ontario. Other countries are following Canada’s lead, exploring and sanctioning the use of serotogenic compounds for medical applications.
Feel confident to buy psychedelics online in Canada and tap into your inner potential through trustworthy sources.
[toc]Main Points:
- Optimi Health, a Vancouver-based startup, has received a drug establishment license to send magic mushroom pills to Australia.
- Australia allows licensed psychiatrists to use magic mushrooms in treating chronic depression.
- The therapy comprises three sessions spanning five to eight weeks, with each session lasting around eight hours.
Rise of Psilocybin Capsules in Canada
Optimi, a Vancouver-based startup, aims to utilize its certification to broaden the pharmaceutical market for psychedelics and secure a competitive edge.
Seven companies have shipped psilocybin, MDMA, or both, exclusively for clinical trials. A spokesperson for Canada’s health department could not confirm whether these exports were for regular patient use, citing company confidentiality for not revealing the enterprises involved.
This milestone places Optimi among a limited number of international suppliers, as the current market tends towards clinical rather than recreational use.
What’s in the Pill?
Although the company has not disclosed the specific mushroom utilized in the pill, they collaborate with a variety of strains such as Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, for the cultivation, testing, and extraction of its psychedelic mushrooms. This quaint town, home to approximately 3,000 inhabitants, is situated three hours east of Vancouver.
The Connection Between Australia and Psychedelic Mushrooms
It’s projected that 1 in 5 Australians, aged 16 to 85, may face a mental health condition. PTSD (post-traumatic stress disorder) could impact 11% of Australians at any stage of their life, while anxiety disorders are prevalent in 17% of the populace.
While there’s an extensive array of treatment options for mental health conditions, not all are effective for every person. Those who don’t respond to certain treatments may struggle to find an approach that works for them, thereby increasing their vulnerability.
Demystifying the Process
Australia has become a frontrunner in employing psilocybin, allowing licensed psychiatrists to use this controlled substance in the treatment of PTSD and treatment-resistant depression.
In a groundbreaking move in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and shrooms for therapeutic use. The TGA affirmed the safety of these substances when used in a medically controlled setting for patients with severe mental disorders.
This advancement has revolutionized the landscape for many mental health professionals and researchers. The usage of these substances will be stringently monitored; it’s not as simple as taking a pill and leaving.
The treatment regimen typically comprises three sessions spread out over five to eight weeks. Each session endures about eight hours, with the therapist accompanying the patient throughout.
Canada’s Role in Psilocybin Research
Canada has surfaced as a prominent center for psilocybin research, significantly advancing our understanding of this compound. Health Canada, in collaboration with several institutions, is leading the investigation into the therapeutic potential of psilocybin in treating various mental health disorders.
Research institutions are no longer required to classify these substances as illegal or rely on unsanctioned dispensaries or mushroom shops. The government now permits certain institutions to grow shrooms for research purposes.
The increased access to substances previously deemed harmful enables researchers to deepen their understanding of their potential benefits to numerous individuals.
A Recurring Trend
The potential of this domain was initially acknowledged back in the 1950s for addressing mental health disorders and substance addiction, including alcoholism. English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer were pioneers in this early research conducted at the Weyburn The Saskatchewan Mental Hospital. The hospital saw significant progress under the leadership of then-premier Tommy Douglas, who provided substantial autonomy to the medical community to explore their medical hypotheses.
Dr. Osmond and Dr. Hoffer ventured into research with LSD, mescaline, and peyote as potential alternatives to the harsh methods of electroshock and lobotomy. Their research took unexpected turns, leading them to advocate for doctors, nurses, and support staff to experiment with these drugs.
Health Research Institutes of Canada
Through the Institute of Neurosciences, Mental Health and Addiction, the Health Research Institutes of Canada is funding three clinical trials to investigate the therapeutic efficiency and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Lead Investigator | Budget for the Project |
| A randomized controlled trial | Psychological distress at end-of-life in advanced-stage cancer patients | University of Toronto | Sarah Hales | $928,643 |
| Investigation of psilocybin psychotherapy mechanisms for treating alcohol use disorder | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial contrasting single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This financial support for research will enable a more thorough understanding of the benefits derived from controlled substances. This has been made feasible by the Canadian Drugs and Substances Strategy (CDSS), initiated by the Government of Canada.
Further Psychedelic Research
Psychiatrists in Vancouver have initiated a phase III clinical trial of MDMA, also known as ecstasy, for treating post-traumatic stress disorder (PTSD). The treatment consists of three eight-hour sessions with MDMA, scheduled a month apart, and nine 90-minute sessions without the drug. Researchers consider this trial as historic due to it being the first clinical examination of an illegal
It has been over forty years since the last time a psychedelic substance was explored.
Getting to Know Psilocybin
Psilocybin is a psychedelic compound that naturally occurs in certain types of mushrooms. Upon consumption, it is metabolized into psilocin, which then stimulates the serotonin 5-HT2a receptors. These receptors are found on the cortical pyramidal cells in the brain, serving as the main processing centers.
Local authorities are investigating the potential of this substance to aid with depression, anxiety, addiction, and end-of-life distress by promoting introspection and spiritual awareness.
Why is it Potentially Effective for Depression, PTSD, and Other Conditions?
The active component of this substance targets multiple areas of the brain, making it potentially beneficial for various mental disorders. A number of patients in Canada and Australia have been treated with this therapy. The reported results are promising, with minor side effects such as temporary anxiety or raised blood pressure.
Impact on Neurobiology
- Serotonin Receptor Activation: This substance functions as a partial agonist at serotonin receptors, particularly the 5-HT2A subtype, which plays a vital role in mood regulation and emotional processing.
- Default Mode Network (DMN) Modulation: The activity in the DMN is reduced, promoting introspection, lessening rigid thinking, and fostering emotional flexibility.
- Activation of Prefrontal and Limbic Regions: The antidepressant effects of the substance are due to its influence on the prefrontal and limbic regions of the brain, including the amygdala. In depressed individuals, the response to emotional stimuli is often reduced. The substance enhances the response to positive emotional stimuli in the right amygdala and decreases or normalizes the response to negative or neutral emotional stimuli.
Psychological and Emotional Effects:
- Fostering Positive Mood States: Fosters feelings of euphoria, interconnectedness, and emotional openness during and after the experience.
- Enhanced Emotional Processing: The psychedelic experience can potentially enable individuals to confront and process deeply embedded emotions, traumatic memories, or existential concerns in a supportive setting.
- Spiritual and Existential Insights: Studies from Johns Hopkins University and Imperial College London suggests that substantial positive transformations, encompassing increased happiness, augmented contentment in life, and spiritual growth, can occur.
Exploring Your Local Magic Mushroom Shops: What’s in Store?
Wondering how this substance might impact your mental health? Feel free to explore magic mushroom stores to discover a product that aligns with your requirements.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Boosts mood, fosters creative thinking, and enhances productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Encourages better wellness and enriches overall life quality |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Spurs clarity, creativity, and concentration. Incorporates a powerful mix of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy benefits |
Worldwide Acceptance of Psilocybin
Canada is not alone in advocating for the usage of magic mushrooms to address mental health concerns. Other countries like Australia are also embracing these hallucinogens to combat conditions such as depression and PTSD. They are procuring premium psychedelic capsules from trustworthy sources. Under suitable supervision, patients can significantly uplift their life quality. Fungalfriend Canada, a vendor of magic mushrooms, offers a wide range of products, from pills to LSD edibles.
Frequently Asked Questions
What are the similarities between psilocybin and MDMA?
Both psilocybin and MDMA have therapeutic capacities in promoting mental health. Psilocybin interacts with serotonin 2A receptors and is effective in managing depression and addiction.
Conversely, MDMA promotes empathy and proves beneficial in PTSD therapy. It exhibits potential in improving emotional processing and
Despite being classified as a controlled substance, it has demonstrated promising therapeutic results.
Is this treatment option accessible to all Australians?
No. In Australia, each individual must undergo an evaluation to ascertain their eligibility for using the substance. The assessment includes factors such as existing heart conditions, any history of psychosis, and more. This treatment is exclusively available to patients who haven’t experienced any improvement from conventional treatments for conditions like depression, anxiety, or PTSD.
What are the implications of Canada exporting mushrooms?
By exporting mushrooms, Canada is positioning itself to lead the psychedelics market, a strategy similar to its approach with cannabis. This could encourage more companies to produce quality products. As a result, Canada may emerge as a global leader in the hallucinogen market, strengthen its economy and increase other countries’ access to these treatments. It would also discourage other countries from obtaining their hallucinogens from illegal dispensaries or suppliers, thus ensuring safety.
Articles of Interest:
